Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | ADA | P00813 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8387304 | 0.83 | HDAC8 (0.55) | HSD17B10ALDH1A1HPGDKDM4EKMO | |
| SCHEMBL27324368 | 0.82 | NOS1 (0.52) | HSD17B10ALDH1A1HPGDKDM4EKMO | |
| SCHEMBL1608442 | 0.79 | HDAC8 (0.55) | — | |
| SCHEMBL11977343 | 0.77 | HDAC8 (0.52) | HSD17B10ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL11976844 | 0.77 | HTR6 (0.56) | HSD17B10ALDH1A1HPGDKDM4EKMO | |
| SCHEMBL11976532 | 0.77 | HTR6 (0.53) | PPARG | |
| SCHEMBL5667825 | 0.77 | CDK4 (0.72) | HSD17B10CDK4CCND1KMT2A | |
| SCHEMBL8685703 | 0.76 | NOS1 (0.51) | HSD17B10ALDH1A1HPGDKDM4EKMO | |
| SCHEMBL8602713 | 0.76 | SLC22A12 (0.63) | HSD17B10ALDH1A1HPGDKDM4EPPARG | |
| SCHEMBL11975783 | 0.74 | EPHX2 (0.47) | ALDH1A1KDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-9359350-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203490-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| WO-2012102405-A1 | RING-FUSED COMPOUND | 佐藤製薬株式会社 (JP) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203490-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | MCL1 2189/4885HSD17B10 2507/4885ALDH1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.